NEUP NEUPHORIA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended March 31, 2026, NEUPHORIA THERAPEUTICS INC reported revenue of n/a, net income of −$505K and diluted EPS of −$0.09; for the fiscal year ended June 2025 revenue was $15.6M.
NEUP annual revenue and earnings
- Fiscal year ended Jun 2025: revenue $15.6M, gross profit n/a, operating income −$1.13M, net income −$370K (margin -2.4%), EPS −$0.23
- Fiscal year ended Jun 2024: revenue n/a, gross profit n/a, operating income −$17.9M, net income −$15.5M (margin n/a), EPS −$18.62
- Fiscal year ended Jun 2023: revenue n/a, gross profit n/a, operating income −$22.0M, net income −$21.4M (margin n/a), EPS −$0.02
NEUP quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue n/a, net income −$505K, EPS −$0.09
- Quarter ended Dec 31, 2025: revenue n/a, net income $1.86M, EPS −$0.77
- Quarter ended Sep 30, 2025: revenue n/a, net income −$9.91M, EPS −$4.41
- Quarter ended Jun 30, 2025 (from the annual report): revenue n/a, net income −$8.88M, EPS −$4.37
- Quarter ended Mar 31, 2025: revenue $15.0M, net income $11.3M, EPS $6.55
- Quarter ended Dec 31, 2024: revenue $663K, net income −$1.94M, EPS −$1.79
- Quarter ended Sep 30, 2024: revenue n/a, net income −$805K, EPS −$0.62
- Quarter ended Jun 30, 2024 (from the annual report): revenue n/a, net income −$2.69M, EPS −$10.48
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.78M, EPS −$2.83
- Quarter ended Dec 31, 2023: revenue n/a, net income −$4.55M, EPS −$5.31
- Quarter ended Sep 30, 2023: revenue n/a, net income −$5.47M, EPS $0.00
NEUP cash flow, buybacks and dividends
- Fiscal year ended Jun 2025: operating cash flow $77.2K, share buybacks n/a
- Fiscal year ended Jun 2024: operating cash flow −$14.7M, share buybacks n/a
- Fiscal year ended Jun 2023: operating cash flow −$14.6M, share buybacks n/a
NEUP balance sheet
- Jun 30, 2026: cash $19.9M, total assets $28.7M, total liabilities $4.11M, shareholders' equity $24.6M
- Mar 31, 2026: cash $19.4M, total assets $34.8M, total liabilities $5.39M, shareholders' equity $29.4M
- Dec 31, 2025: cash $22.2M, total assets $36.6M, total liabilities $6.90M, shareholders' equity $29.7M
- Sep 30, 2025: cash $13.6M, total assets $27.3M, total liabilities $14.8M, shareholders' equity $12.5M
- Jun 30, 2025: cash $14.2M, total assets $28.6M, total liabilities $9.59M, shareholders' equity $19.0M
- Mar 31, 2025: cash $17.0M, total assets $30.7M, total liabilities $4.72M, shareholders' equity $26.0M
- Dec 31, 2024: cash $4.34M, total assets $18.2M, total liabilities $4.42M, shareholders' equity $13.7M
- Sep 30, 2024: cash $8.08M, total assets $22.9M, total liabilities $5.85M, shareholders' equity $17.1M
What is NEUP's revenue?
NEUPHORIA THERAPEUTICS INC reported $15.6M of revenue for the fiscal year ended June 2025.
Is NEUP profitable?
No. NEUPHORIA THERAPEUTICS INC lost $17.4M over the last four quarters.
What is NEUP's EPS?
Diluted earnings per share over the last four quarters were −$9.64; −$0.09 in the latest quarter.